Drug Trial Radar · NCT06381661
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jul 9, 2026
Primary completion
Aug 9, 2028
Study completion Jul 9, 2031
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 37 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.
Conditions
- Sepsis
Interventions
TocilizumabDrug
8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
BaricitinibDrug
4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
AnakinraDrug
100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
HydrocortisoneDrug
50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
Hydrocortisone and fludrocortisoneDrug
Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
HeparinDrug
Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
Low molecular weight heparinDrug
Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
Recombinant humanThrombomodulin( rhTM)Drug
Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
SivelestatDrug
0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)
Usual careOther
Usual care
blood purification with MTx.100 Plasma Adsorption ColumnOther
up to 4 hours a day, up to four days in a row
G-CSF filgrastimDrug
0.5 MIU (5μg)/kg/day subcutaneously for 5 consecutive days (or up to ICU discharge pending which occurs first) - same for adults and children .
Interferon gamma-1bDrug
rhIFNg subcutaneously at 50 µg/m2 if body surface \>0,5 m2, or 1.5µg/kg if body surface of 0,5 m2or less, every other day for 15 days (or up to ICU discharge pending which occurs first)
FludrocortisoneDrug
50µg orally (or via the gastric tube) once a day for 7 days (or ICU discharge pending which will occur first) (same for adults and children)
Prophylactic unfractionated heparin (UFH)Drug
100 IU/kg/24h for 6 days
Octaplas LGDrug
12 mL/kg on day 1; repeated daily from day 2 to day 5, provided that PT/INR remains ≥ 1.40 (This intervention will be opened for randomisation once a supply circuit is in place)
PlasminogenDrug
2,2 mg/kg/day (intravenous infusion) during 3 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: At day 28
- Number of days alive without persistent life-supportive therapiesTime frame: At day 28
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
CHU Dijon - infectiologie
Dijon, France · Recruiting
CHU Dijon - réanimation adulte
Dijon, France · Recruiting
CH Sud Essonne - site d'Etampes - Réanimation adulte
Étampes, France · Not yet recruiting
Hôpital Raymond Poincaré - infectiologie
Garches, France · Recruiting
Hôpital Raymond Poincaré
Garches, France · Recruiting
CH de Haguenau
Haguenau, France · Recruiting
CHD Vendée - infectiologie
La Roche-sur-Yon, France · Recruiting
CHD Vendée - réanimation adulte
La Roche-sur-Yon, France · Recruiting
CH Le Mans - Réanimation adulte
Le Mans, France · Not yet recruiting
CHRU Nancy - Hôpital Central - Réanimation adulte
Nancy, France · Recruiting
CHU Nantes - Hôpital Hôtel Dieu - Infectiologie
Nantes, France · Not yet recruiting
CHU Nantes - Hôpital Hôtel Dieu - Réanimation adulte
Nantes, France · Not yet recruiting
AP-HP Hôpital Bichat - Réanimation adulte
Paris, France · Recruiting
AP-HP Hôpital Bicêtre - Infectiologie
Paris, France · Not yet recruiting
AP-HP Hôpital Bicêtre - Réanimation adulte
Paris, France · Not yet recruiting
Hôpital Saint Antoine AP-HP - infectiologie
Paris, France · Recruiting
Hôpital Saint Antoine AP-HP - réanimation adulte
Paris, France · Recruiting
CHU Strasbourg - Hôpital Civil (NHC) - Réanimation adulte
Strasbourg, France · Not yet recruiting
CH Tourcoing
Tourcoing, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.